Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

Anti-polysaccharide and anti-diphtheria protective antibodies after 13-valent pneumococcal conjugate vaccination in rheumatoid arthritis patients under immunosuppressive therapy

Copyright © 2018 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 195(2018) vom: 01. Okt., Seite 18-27
1. Verfasser: Caporuscio, Sara (VerfasserIn)
Weitere Verfasser: Ieraci, Roberto, Valesini, Guido, Teloni, Raffaela, Mariotti, Sabrina, Spinelli, Francesca Romana, Ferlito, Claudia, Salemi, Simonetta, Picchianti Diamanti, Andrea, Meneguzzi, Giorgia, Markovic, Milica, Sgrulletti, Mayla, von Hunolstein, Christina, Ralli, Luisa, Pinto, Antonietta, Salerno, Gerardo, Canzoni, Marco, Sorgi, Maria Laura, Laganà, Bruno, Di Rosa, Roberta, Nisini, Roberto, D'Amelio, Raffaele
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2018
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't 13-valent pneumococcal conjugate vaccine Antibody persistence Immunogenicity Immunosuppressive therapy Rheumatoid arthritis 13-valent pneumococcal vaccine Antibodies, Bacterial Immunoglobulin G mehr... Immunosuppressive Agents Pneumococcal Vaccines Polysaccharides, Bacterial
Beschreibung
Zusammenfassung:Copyright © 2018 Elsevier Inc. All rights reserved.
Immunogenicity of 13-valent pneumococcal polysaccharide (PnPS) conjugate vaccine (PCV13) was evaluated in 38 rheumatoid arthritis patients under immunosuppressive treatment and 20 healthy controls (HC). Antibodies to all PnPS and diphtheria-toxin analogue conjugate protein were measured pre- (T0), 1 (T1), 6 (T2), 12 (T3) months post-immunization. Patients and HC had similar response to individual PnPS. Mean antibody levels to all PnPS but one doubled at T1 compared with T0, with T3 persistence for only 8-7/13 PnPS. Baseline antibody levels was inversely associated with the rate of responders at T1 (T1/T0≥2) to 11/13 PnPS. Few subjects reached protective IgG levels against some serotypes frequently isolated in Italian patients with invasive pneumococcal disease. Antibody response was not influenced by therapy, except the one to PS7F, which was reduced by tumor necrosis factor-α-inhibitors. Vaccination increased also anti-diphtheria IgG. Despite this study substantially confirmed the PCV13 immunogenicity in immunocompromised patients, it also revealed some limitations
Beschreibung:Date Completed 27.08.2019
Date Revised 27.08.2019
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2018.07.010